JP2000256323A
(en)
*
|
1999-01-08 |
2000-09-19 |
Japan Tobacco Inc |
2-oxoquinoline compound and its medicinal use
|
ATE428495T1
(en)
*
|
1999-04-28 |
2009-05-15 |
Toray Industries |
MATERIALS FOR REMOVING CANNABINOIDS AND COLUMNS WITH THESE MATERIALS FOR REMOVING CANNABINOIDS
|
US8449908B2
(en)
|
2000-12-22 |
2013-05-28 |
Alltranz, Llc |
Transdermal delivery of cannabidiol
|
KR20030070082A
(en)
*
|
2000-12-28 |
2003-08-27 |
시오노기세이야쿠가부시키가이샤 |
Pyridone derivative having affinity for cannabinoid 2-type receptor
|
CA2440186C
(en)
|
2001-03-08 |
2009-01-13 |
Shionogi & Co., Ltd. |
Medicinal composition containing 1,3-thiazine derivative
|
AU2002319627A1
(en)
|
2001-07-20 |
2003-03-03 |
Merck And Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
WO2003061699A1
(en)
*
|
2001-12-27 |
2003-07-31 |
Japan Tobacco, Inc. |
Remedies for allergic diseases
|
EP2130820A1
(en)
|
2002-02-19 |
2009-12-09 |
Shionogi & Co., Ltd. |
Antipruritics
|
CA2478338A1
(en)
|
2002-03-08 |
2003-09-18 |
Signal Pharmaceuticals, Inc. |
Combination therapy for treating, preventing or managing proliferative disorders and cancers
|
EP1496838B1
(en)
|
2002-03-12 |
2010-11-03 |
Merck Sharp & Dohme Corp. |
Substituted amides
|
CA2479618A1
(en)
|
2002-03-26 |
2003-10-09 |
William K. Hagmann |
Spirocyclic amides as cannabinoid receptor modulators
|
AU2003225964B2
(en)
|
2002-03-28 |
2008-11-20 |
Merck Sharp & Dohme Corp. |
Substituted 2,3-diphenyl pyridines
|
AU2003223510B2
(en)
|
2002-04-12 |
2008-05-08 |
Merck Sharp & Dohme Corp. |
Bicyclic amides
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
ES2294330T3
(en)
|
2002-08-02 |
2008-04-01 |
MERCK & CO., INC. |
FURO DERIVATIVES (2,3-B) SUBSTITUTED PYRIDINE.
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1644335A4
(en)
|
2003-07-11 |
2008-06-04 |
Bristol Myers Squibb Co |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
TW200508211A
(en)
|
2003-08-26 |
2005-03-01 |
Shionogi & Co |
2-naphthylimino-1,3-thiazine derivatives
|
EP1669350B1
(en)
|
2003-09-22 |
2012-02-29 |
Msd K.K. |
Piperidine derivatives
|
US7728141B2
(en)
|
2003-11-04 |
2010-06-01 |
Merck Sharp & Dohme Corp. |
Substituted naphthyridinone derivatives
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
IL160420A0
(en)
|
2004-02-16 |
2004-07-25 |
Yissum Res Dev Co |
Treating or preventing diabetes with cannabidiol
|
JP2007530690A
(en)
|
2004-03-29 |
2007-11-01 |
メルク エンド カムパニー インコーポレーテッド |
Diaryltriazoles as inhibitors of 11-β-hydroxysteroid dehydrogenase-1
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
ATE472531T1
(en)
|
2004-08-06 |
2010-07-15 |
Merck Sharp & Dohme |
SULFONYL COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE-1
|
TWI360539B
(en)
|
2004-10-28 |
2012-03-21 |
Shionogi & Co |
3-carbamoyl-2-pyridone derivatives
|
DK1814590T4
(en)
|
2004-11-01 |
2014-02-24 |
Amylin Pharmaceuticals Llc |
Treatment of obesity and related diseases.
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
WO2006129826A1
(en)
|
2005-05-30 |
2006-12-07 |
Banyu Pharmaceutical Co., Ltd. |
Novel piperidine derivative
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
PL1902034T3
(en)
|
2005-06-02 |
2011-09-30 |
Glenmark Pharmaceuticals Sa |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
EP1916239A4
(en)
|
2005-08-10 |
2009-10-21 |
Banyu Pharma Co Ltd |
Pyridone compound
|
BRPI0614649A2
(en)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
hybrid polypeptides with selectable properties
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
DE602006017712D1
(en)
|
2005-08-24 |
2010-12-02 |
Banyu Pharma Co Ltd |
PHENYLPYRIDONDERIVAT
|
EP1939194A4
(en)
|
2005-09-07 |
2010-12-08 |
Banyu Pharma Co Ltd |
Bicyclic aromatic substituted pyridone derivative
|
JP4879988B2
(en)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
AU2006307046A1
(en)
|
2005-10-27 |
2007-05-03 |
Msd K.K. |
Novel benzoxathiin derivative
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
EP1801098A1
(en)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
JPWO2008038692A1
(en)
|
2006-09-28 |
2010-01-28 |
萬有製薬株式会社 |
Diaryl ketimine derivatives
|
EP1935420A1
(en)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
|
EP2145884B1
(en)
|
2007-04-02 |
2014-08-06 |
Msd K.K. |
Indoledione derivative
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
WO2009110510A1
(en)
|
2008-03-06 |
2009-09-11 |
萬有製薬株式会社 |
Alkylaminopyridine derivative
|
WO2009119726A1
(en)
|
2008-03-28 |
2009-10-01 |
萬有製薬株式会社 |
Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
WO2009154132A1
(en)
|
2008-06-19 |
2009-12-23 |
萬有製薬株式会社 |
Spirodiamine-diarylketoxime derivative
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
AU2009277736A1
(en)
|
2008-07-30 |
2010-02-04 |
Banyu Pharmaceutical Co., Ltd. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
EP2348857B1
(en)
|
2008-10-22 |
2016-02-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CN102272103B
(en)
|
2008-10-30 |
2015-10-21 |
默沙东公司 |
Isonicotinamide orexin receptor antagonists
|
EP2362731B1
(en)
|
2008-10-31 |
2016-04-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US8759539B2
(en)
|
2008-11-17 |
2014-06-24 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
EP2379547A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
EP2379562A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011508A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
CA2779088A1
(en)
|
2009-11-16 |
2011-05-19 |
Mellitech |
[1,5]-diazocin derivatives
|
CN103664873B
(en)
|
2009-12-30 |
2016-06-15 |
深圳信立泰药业股份有限公司 |
As 3-(3-amino piperidine-1-yl)-5-oxo-1 of DPP IV (DPP-IV) inhibitor, 2,4-pyrrolotriazine derivatives
|
AU2011218830B2
(en)
|
2010-02-25 |
2014-07-24 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
EP2563764B1
(en)
|
2010-04-26 |
2015-02-25 |
Merck Sharp & Dohme Corp. |
Novel spiropiperidine prolylcarboxypeptidase inhibitors
|
WO2011143057A1
(en)
|
2010-05-11 |
2011-11-17 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
WO2011156246A1
(en)
|
2010-06-11 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
KR101668514B1
(en)
|
2011-02-25 |
2016-10-21 |
머크 샤프 앤드 돔 코포레이션 |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
AR088352A1
(en)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
|
KR20150036245A
(en)
|
2012-08-02 |
2015-04-07 |
머크 샤프 앤드 돔 코포레이션 |
Antidiabetic tricyclic compounds
|
CN104994848A
(en)
|
2013-02-22 |
2015-10-21 |
默沙东公司 |
Antidiabetic bicyclic compounds
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
RU2746405C2
(en)
|
2014-08-29 |
2021-04-13 |
Тес Фарма С.Р.Л. |
Inhibitors - amino - carboxymuconate - semialdehyde - decarboxylase
|
KR20190065312A
(en)
|
2016-10-14 |
2019-06-11 |
테스 파마 에스.알.엘. |
Inhibitors of alpha-amino-beta-carboxy-muconic acid semialdehyde decarboxylase
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
TW202033516A
(en)
|
2018-11-20 |
2020-09-16 |
義大利商Tes製藥(股份)責任有限公司 |
Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
EP4010314B1
(en)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
WO2021050786A1
(en)
*
|
2019-09-10 |
2021-03-18 |
California Amber Inc. |
Cannabin oid compositions with improved organoleptic and therapeutic properties, method of production, and use thereof
|
CA3189908A1
(en)
|
2020-08-18 |
2022-02-24 |
Stephane L. Bogen |
Bicycloheptane pyrrolidine orexin receptor agonists
|